Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry

Stereotactic body radiotherapy (SBRT) is an emerging treatment option for liver metastases in patients unsuitable for surgery. We investigated factors associated with clinical outcomes for liver metastases treated with SBRT from a multi-center, international patient registry. Patients with liver met...

Full description

Saved in:
Bibliographic Details
Published in:Radiation oncology (London, England) England), 2018-02, Vol.13 (1), p.26-26, Article 26
Main Authors: Mahadevan, Anand, Blanck, Oliver, Lanciano, Rachelle, Peddada, Anuj, Sundararaman, Srinath, D'Ambrosio, David, Sharma, Sanjeev, Perry, David, Kolker, James, Davis, Joanne
Format: Article
Language:English
Subjects:
Care and treatment
Diagnosis
Liver metastasis
Metastasis
Radiotherapy
RSSearch registry
SBRT
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c598t-d0244b933b1bb10f7c432e1ee6d292b76614e41c0c74704edc996926f62301f63
cites cdi_FETCH-LOGICAL-c598t-d0244b933b1bb10f7c432e1ee6d292b76614e41c0c74704edc996926f62301f63
container_end_page 26
container_issue 1
container_start_page 26
container_title Radiation oncology (London, England)
container_volume 13
creator Mahadevan, Anand
Blanck, Oliver
Lanciano, Rachelle
Peddada, Anuj
Sundararaman, Srinath
D'Ambrosio, David
Sharma, Sanjeev
Perry, David
Kolker, James
Davis, Joanne
description Stereotactic body radiotherapy (SBRT) is an emerging treatment option for liver metastases in patients unsuitable for surgery. We investigated factors associated with clinical outcomes for liver metastases treated with SBRT from a multi-center, international patient registry. Patients with liver metastases treated with SBRT were identified in the RSSearch® Patient Registry. Patient, tumor and treatment characteristics associated with treatment outcomes were assessed. Dose fractionations were normalized to BED . Overall survival (OS) and local control (LC) were evaluated using Kaplan Meier analysis and log-rank test. The study included 427 patients with 568 liver metastases from 25 academic and community-based centers. Median age was 67 years (31-91 years). Colorectal adenocarcinoma (CRC) was the most common primary cancer. 73% of patients received prior chemotherapy. Median tumor volume was 40 cm (1.6-877 cm ), median SBRT dose was 45 Gy (12-60 Gy) delivered in a median of 3 fractions [1-5]. At a median follow-up of 14 months (1-91 months) the median overall survival (OS) was 22 months. Median OS was greater for patients with CRC (27 mo), breast (21 mo) and gynecological (25 mo) metastases compared to lung (10 mo), other gastro-intestinal (GI) (18 mo) and pancreatic (6 mo) primaries (p 
doi_str_mv 10.1186/s13014-018-0969-2
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_820ccb26edd344e08e7bf6543a400102</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A527509003</galeid><doaj_id>oai_doaj_org_article_820ccb26edd344e08e7bf6543a400102</doaj_id><sourcerecordid>A527509003</sourcerecordid><originalsourceid>FETCH-LOGICAL-c598t-d0244b933b1bb10f7c432e1ee6d292b76614e41c0c74704edc996926f62301f63</originalsourceid><addsrcrecordid>eNptUstq3DAUNaWlSdN-QDdF0E26cHoly5a1KSShj0CgZSaF7oQsX88o2NZEkgPzIf2NfkS_rHJnGjJQJJC495xzH5wse03hjNK6eh9oAZTnQOscZCVz9iQ7poLXuaDix9NH_6PsRQi3ALwsQD7PjpjkhRQgjrOfy4geXdQmWkMuXLslC91aF9fo9WZLTpcXi5t3pHOe9PYePRkw6pCuDSQnprejNbonborGDRhI591AEpnYMQmPOlo3pvww9dHmdgzRxmkfWyyXqL1Z__5FviUcjpEscGVD9NuX2bNO9wFf7d-T7PunjzeXX_Lrr5-vLs-vc1PKOuYtMM4bWRQNbRoKnTC8YEgRq5ZJ1oiqohw5NWAEF8CxNTKtiVVdxdLiuqo4ya52uq3Tt2rj7aD9Vjlt1d-A8yulfVpMj6pmYEzDKmzbgnOEGkXTVSUvNAegwJLWh53WZmqGVCrN43V_IHqYGe1ardy9KmtKpRBJ4HQv4N3dhCGqwQaDfa9HdFNQDIAxKjmda73dQVc6tWbHziVFM8PVeclECRKgSKiz_6DSaXGwxo3Y2RQ_INAdwXgXgsfuoXsKanac2jlOJcep2XFqbuXN47EfGP8sVvwBdljTgg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2002219412</pqid></control><display><type>article</type><title>Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Mahadevan, Anand ; Blanck, Oliver ; Lanciano, Rachelle ; Peddada, Anuj ; Sundararaman, Srinath ; D'Ambrosio, David ; Sharma, Sanjeev ; Perry, David ; Kolker, James ; Davis, Joanne</creator><creatorcontrib>Mahadevan, Anand ; Blanck, Oliver ; Lanciano, Rachelle ; Peddada, Anuj ; Sundararaman, Srinath ; D'Ambrosio, David ; Sharma, Sanjeev ; Perry, David ; Kolker, James ; Davis, Joanne</creatorcontrib><description>Stereotactic body radiotherapy (SBRT) is an emerging treatment option for liver metastases in patients unsuitable for surgery. We investigated factors associated with clinical outcomes for liver metastases treated with SBRT from a multi-center, international patient registry. Patients with liver metastases treated with SBRT were identified in the RSSearch® Patient Registry. Patient, tumor and treatment characteristics associated with treatment outcomes were assessed. Dose fractionations were normalized to BED . Overall survival (OS) and local control (LC) were evaluated using Kaplan Meier analysis and log-rank test. The study included 427 patients with 568 liver metastases from 25 academic and community-based centers. Median age was 67 years (31-91 years). Colorectal adenocarcinoma (CRC) was the most common primary cancer. 73% of patients received prior chemotherapy. Median tumor volume was 40 cm (1.6-877 cm ), median SBRT dose was 45 Gy (12-60 Gy) delivered in a median of 3 fractions [1-5]. At a median follow-up of 14 months (1-91 months) the median overall survival (OS) was 22 months. Median OS was greater for patients with CRC (27 mo), breast (21 mo) and gynecological (25 mo) metastases compared to lung (10 mo), other gastro-intestinal (GI) (18 mo) and pancreatic (6 mo) primaries (p &lt; 0.0001). Smaller tumor volumes (&lt; 40 cm ) correlated with improved OS (25 months vs 15 months p = 0.0014). BED  ≥ 100 Gy was also associated with improved OS (27 months vs 15 months p &lt; 0.0001). Local control (LC) was evaluable in 430 liver metastases from 324 patients. Two-year LC rates was better for BED  ≥ 100 Gy (77.2% vs 59.6%) and the median LC was better for tumors &lt; 40 cm (52 vs 39 months). There was no difference in LC based on histology of the primary tumor. In a large, multi-institutional series of patients with liver metastasis treated with SBRT, reasonable LC and OS was observed. OS and LC depended on dose and tumor volume, while OS varied by primary tumor. Future prospective trials on the role of SBRT for liver metastasis from different primaries in the setting of multidisciplinary management including systemic therapy, is warranted. Clinicaltrials.gov: NCT01885299 .</description><identifier>ISSN: 1748-717X</identifier><identifier>EISSN: 1748-717X</identifier><identifier>DOI: 10.1186/s13014-018-0969-2</identifier><identifier>PMID: 29439707</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Care and treatment ; Diagnosis ; Liver metastasis ; Metastasis ; Radiotherapy ; RSSearch registry ; SBRT</subject><ispartof>Radiation oncology (London, England), 2018-02, Vol.13 (1), p.26-26, Article 26</ispartof><rights>COPYRIGHT 2018 BioMed Central Ltd.</rights><rights>The Author(s). 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c598t-d0244b933b1bb10f7c432e1ee6d292b76614e41c0c74704edc996926f62301f63</citedby><cites>FETCH-LOGICAL-c598t-d0244b933b1bb10f7c432e1ee6d292b76614e41c0c74704edc996926f62301f63</cites><orcidid>0000-0003-3555-4217</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811977/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811977/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,36992,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29439707$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mahadevan, Anand</creatorcontrib><creatorcontrib>Blanck, Oliver</creatorcontrib><creatorcontrib>Lanciano, Rachelle</creatorcontrib><creatorcontrib>Peddada, Anuj</creatorcontrib><creatorcontrib>Sundararaman, Srinath</creatorcontrib><creatorcontrib>D'Ambrosio, David</creatorcontrib><creatorcontrib>Sharma, Sanjeev</creatorcontrib><creatorcontrib>Perry, David</creatorcontrib><creatorcontrib>Kolker, James</creatorcontrib><creatorcontrib>Davis, Joanne</creatorcontrib><title>Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry</title><title>Radiation oncology (London, England)</title><addtitle>Radiat Oncol</addtitle><description>Stereotactic body radiotherapy (SBRT) is an emerging treatment option for liver metastases in patients unsuitable for surgery. We investigated factors associated with clinical outcomes for liver metastases treated with SBRT from a multi-center, international patient registry. Patients with liver metastases treated with SBRT were identified in the RSSearch® Patient Registry. Patient, tumor and treatment characteristics associated with treatment outcomes were assessed. Dose fractionations were normalized to BED . Overall survival (OS) and local control (LC) were evaluated using Kaplan Meier analysis and log-rank test. The study included 427 patients with 568 liver metastases from 25 academic and community-based centers. Median age was 67 years (31-91 years). Colorectal adenocarcinoma (CRC) was the most common primary cancer. 73% of patients received prior chemotherapy. Median tumor volume was 40 cm (1.6-877 cm ), median SBRT dose was 45 Gy (12-60 Gy) delivered in a median of 3 fractions [1-5]. At a median follow-up of 14 months (1-91 months) the median overall survival (OS) was 22 months. Median OS was greater for patients with CRC (27 mo), breast (21 mo) and gynecological (25 mo) metastases compared to lung (10 mo), other gastro-intestinal (GI) (18 mo) and pancreatic (6 mo) primaries (p &lt; 0.0001). Smaller tumor volumes (&lt; 40 cm ) correlated with improved OS (25 months vs 15 months p = 0.0014). BED  ≥ 100 Gy was also associated with improved OS (27 months vs 15 months p &lt; 0.0001). Local control (LC) was evaluable in 430 liver metastases from 324 patients. Two-year LC rates was better for BED  ≥ 100 Gy (77.2% vs 59.6%) and the median LC was better for tumors &lt; 40 cm (52 vs 39 months). There was no difference in LC based on histology of the primary tumor. In a large, multi-institutional series of patients with liver metastasis treated with SBRT, reasonable LC and OS was observed. OS and LC depended on dose and tumor volume, while OS varied by primary tumor. Future prospective trials on the role of SBRT for liver metastasis from different primaries in the setting of multidisciplinary management including systemic therapy, is warranted. Clinicaltrials.gov: NCT01885299 .</description><subject>Care and treatment</subject><subject>Diagnosis</subject><subject>Liver metastasis</subject><subject>Metastasis</subject><subject>Radiotherapy</subject><subject>RSSearch registry</subject><subject>SBRT</subject><issn>1748-717X</issn><issn>1748-717X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNptUstq3DAUNaWlSdN-QDdF0E26cHoly5a1KSShj0CgZSaF7oQsX88o2NZEkgPzIf2NfkS_rHJnGjJQJJC495xzH5wse03hjNK6eh9oAZTnQOscZCVz9iQ7poLXuaDix9NH_6PsRQi3ALwsQD7PjpjkhRQgjrOfy4geXdQmWkMuXLslC91aF9fo9WZLTpcXi5t3pHOe9PYePRkw6pCuDSQnprejNbonborGDRhI591AEpnYMQmPOlo3pvww9dHmdgzRxmkfWyyXqL1Z__5FviUcjpEscGVD9NuX2bNO9wFf7d-T7PunjzeXX_Lrr5-vLs-vc1PKOuYtMM4bWRQNbRoKnTC8YEgRq5ZJ1oiqohw5NWAEF8CxNTKtiVVdxdLiuqo4ya52uq3Tt2rj7aD9Vjlt1d-A8yulfVpMj6pmYEzDKmzbgnOEGkXTVSUvNAegwJLWh53WZmqGVCrN43V_IHqYGe1ardy9KmtKpRBJ4HQv4N3dhCGqwQaDfa9HdFNQDIAxKjmda73dQVc6tWbHziVFM8PVeclECRKgSKiz_6DSaXGwxo3Y2RQ_INAdwXgXgsfuoXsKanac2jlOJcep2XFqbuXN47EfGP8sVvwBdljTgg</recordid><startdate>20180213</startdate><enddate>20180213</enddate><creator>Mahadevan, Anand</creator><creator>Blanck, Oliver</creator><creator>Lanciano, Rachelle</creator><creator>Peddada, Anuj</creator><creator>Sundararaman, Srinath</creator><creator>D'Ambrosio, David</creator><creator>Sharma, Sanjeev</creator><creator>Perry, David</creator><creator>Kolker, James</creator><creator>Davis, Joanne</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3555-4217</orcidid></search><sort><creationdate>20180213</creationdate><title>Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry</title><author>Mahadevan, Anand ; Blanck, Oliver ; Lanciano, Rachelle ; Peddada, Anuj ; Sundararaman, Srinath ; D'Ambrosio, David ; Sharma, Sanjeev ; Perry, David ; Kolker, James ; Davis, Joanne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c598t-d0244b933b1bb10f7c432e1ee6d292b76614e41c0c74704edc996926f62301f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Care and treatment</topic><topic>Diagnosis</topic><topic>Liver metastasis</topic><topic>Metastasis</topic><topic>Radiotherapy</topic><topic>RSSearch registry</topic><topic>SBRT</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mahadevan, Anand</creatorcontrib><creatorcontrib>Blanck, Oliver</creatorcontrib><creatorcontrib>Lanciano, Rachelle</creatorcontrib><creatorcontrib>Peddada, Anuj</creatorcontrib><creatorcontrib>Sundararaman, Srinath</creatorcontrib><creatorcontrib>D'Ambrosio, David</creatorcontrib><creatorcontrib>Sharma, Sanjeev</creatorcontrib><creatorcontrib>Perry, David</creatorcontrib><creatorcontrib>Kolker, James</creatorcontrib><creatorcontrib>Davis, Joanne</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Radiation oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mahadevan, Anand</au><au>Blanck, Oliver</au><au>Lanciano, Rachelle</au><au>Peddada, Anuj</au><au>Sundararaman, Srinath</au><au>D'Ambrosio, David</au><au>Sharma, Sanjeev</au><au>Perry, David</au><au>Kolker, James</au><au>Davis, Joanne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry</atitle><jtitle>Radiation oncology (London, England)</jtitle><addtitle>Radiat Oncol</addtitle><date>2018-02-13</date><risdate>2018</risdate><volume>13</volume><issue>1</issue><spage>26</spage><epage>26</epage><pages>26-26</pages><artnum>26</artnum><issn>1748-717X</issn><eissn>1748-717X</eissn><abstract>Stereotactic body radiotherapy (SBRT) is an emerging treatment option for liver metastases in patients unsuitable for surgery. We investigated factors associated with clinical outcomes for liver metastases treated with SBRT from a multi-center, international patient registry. Patients with liver metastases treated with SBRT were identified in the RSSearch® Patient Registry. Patient, tumor and treatment characteristics associated with treatment outcomes were assessed. Dose fractionations were normalized to BED . Overall survival (OS) and local control (LC) were evaluated using Kaplan Meier analysis and log-rank test. The study included 427 patients with 568 liver metastases from 25 academic and community-based centers. Median age was 67 years (31-91 years). Colorectal adenocarcinoma (CRC) was the most common primary cancer. 73% of patients received prior chemotherapy. Median tumor volume was 40 cm (1.6-877 cm ), median SBRT dose was 45 Gy (12-60 Gy) delivered in a median of 3 fractions [1-5]. At a median follow-up of 14 months (1-91 months) the median overall survival (OS) was 22 months. Median OS was greater for patients with CRC (27 mo), breast (21 mo) and gynecological (25 mo) metastases compared to lung (10 mo), other gastro-intestinal (GI) (18 mo) and pancreatic (6 mo) primaries (p &lt; 0.0001). Smaller tumor volumes (&lt; 40 cm ) correlated with improved OS (25 months vs 15 months p = 0.0014). BED  ≥ 100 Gy was also associated with improved OS (27 months vs 15 months p &lt; 0.0001). Local control (LC) was evaluable in 430 liver metastases from 324 patients. Two-year LC rates was better for BED  ≥ 100 Gy (77.2% vs 59.6%) and the median LC was better for tumors &lt; 40 cm (52 vs 39 months). There was no difference in LC based on histology of the primary tumor. In a large, multi-institutional series of patients with liver metastasis treated with SBRT, reasonable LC and OS was observed. OS and LC depended on dose and tumor volume, while OS varied by primary tumor. Future prospective trials on the role of SBRT for liver metastasis from different primaries in the setting of multidisciplinary management including systemic therapy, is warranted. Clinicaltrials.gov: NCT01885299 .</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>29439707</pmid><doi>10.1186/s13014-018-0969-2</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-3555-4217</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1748-717X
ispartof Radiation oncology (London, England), 2018-02, Vol.13 (1), p.26-26, Article 26
issn 1748-717X
1748-717X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_820ccb26edd344e08e7bf6543a400102
source Publicly Available Content Database; PubMed Central
subjects Care and treatment
Diagnosis
Liver metastasis
Metastasis
Radiotherapy
RSSearch registry
SBRT
title Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T17%3A21%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stereotactic%20Body%20Radiotherapy%20(SBRT)%20for%20liver%20metastasis%20-%20clinical%20outcomes%20from%20the%20international%20multi-institutional%20RSSearch%C2%AE%20Patient%20Registry&rft.jtitle=Radiation%20oncology%20(London,%20England)&rft.au=Mahadevan,%20Anand&rft.date=2018-02-13&rft.volume=13&rft.issue=1&rft.spage=26&rft.epage=26&rft.pages=26-26&rft.artnum=26&rft.issn=1748-717X&rft.eissn=1748-717X&rft_id=info:doi/10.1186/s13014-018-0969-2&rft_dat=%3Cgale_doaj_%3EA527509003%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c598t-d0244b933b1bb10f7c432e1ee6d292b76614e41c0c74704edc996926f62301f63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2002219412&rft_id=info:pmid/29439707&rft_galeid=A527509003&rfr_iscdi=true